Welcome to the research group led by Mouldy Sioud: Immunomodulation and Targeted Therapies

Mouldy Sioud
Mouldy Sioud

Group leader:  Mouldy Sioud, DEA Pharm, PhD, Dr Philos

Immunotherapy is based on the generally-accepted hypothesis that the immune system is the best tool humans have for fighting disease. However, despite the advances made in this area, a large proportion of cancer patients showed primary or acquired resistance to current cancer immunotherapies. Most mechanisms driving resistance to therapies are thought to be cancer cell-autonomous, but nonmalignant host cells within the tumor microenvironment could have important roles in both chemo and immunotherapy failure. For example, stromal cells such as macrophages and monocytic myeloid derived suppressor cells express T cell immune checkpoint ligands and immunosuppressive factors such IL-10 and indoleamine 2,3-dioxygenase (IDO), which inhibit T cell responses against tumors. Although co-inhibitory signals expressed by immune cells are important both for the prevention of inappropriate autoimmune responses against self-antigens and termination of normal immune responses once initiated, they represent a huge barrier to the induction of therapeutic anti-cancer immunity. Hence, current therapies should target all these tumor-promoting factors to be effective and result in improved patient outcomes. The principal objective of our work is (i) to develop new targeted antibody- and peptide-based therapies to kill tumor cells and/or immunosuppressive cells, and (ii) to unleash anti-tumor immunity using RNA interference and CRISPR technologies.

Relevant teaching reviews on the topics

Contact information:
Department of Immunology, Institute for Cancer Research
The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway
Telephone (047) 22 78 14 14 (Sioud) Email: mouldy.sioud@rr-research.no